# Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

> **NCT00326911** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **BIOLOGICAL:** bevacizumab
- **DRUG:** gemcitabine
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT00326911
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** The planned enrollment was 130 patients and the study was halted prematurely due to lack of efficacy in both arms. Enrolled patients continued treatment.
- **Last updated:** 2011-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326911, "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00326911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*